{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:54:04Z","timestamp":1784843644718,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Nabriva Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,13]]},"abstract":"<jats:p>Monotherapy with lefamulin, a novel, pleuromutilin antibiotic with intravenous and oral formulation options, was noninferior to moxifloxacin for efficacy and generally safe and well tolerated for community-acquired bacterial pneumonia (CABP). Lefamulin\u2019s spectrum of activity targets bacteria that cause CABP.<\/jats:p>","DOI":"10.1093\/cid\/ciz090","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T20:06:45Z","timestamp":1548619605000},"page":"1856-1867","source":"Crossref","is-referenced-by-count":122,"title":["Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial"],"prefix":"10.1093","volume":"69","author":[{"suffix":"Jr","given":"Thomas M","family":"File","sequence":"first","affiliation":[{"name":"Summa Health, Akron, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Das","sequence":"additional","affiliation":[{"name":"Das Consulting, Guerneville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Saviski","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P","family":"Gelone","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Seltzer","sequence":"additional","affiliation":[{"name":"Urogen Pharma, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Paukner","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang W","family":"Wicha","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George H","family":"Talbot","sequence":"additional","affiliation":[{"name":"Talbot Advisors LLC, Anna Maria, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne B","family":"Gasink","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"2019111315314394200_CIT0001","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111315314394200_CIT0002","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/infdis\/jit506","article-title":"Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged \u226550 years with community-acquired pneumonia","volume":"208","author":"Sherwin","year":"2013","journal-title":"J Infect Dis"},{"key":"2019111315314394200_CIT0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"2019111315314394200_CIT0004","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","article-title":"Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia","volume":"62","author":"Gadsby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019111315314394200_CIT0005","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1378\/chest.125.5.1913","article-title":"Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?","volume":"125","author":"Cunha","year":"2004","journal-title":"Chest"},{"key":"2019111315314394200_CIT0006","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019111315314394200_CIT0007","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.200603-350OC","article-title":"A worldwide perspective of atypical pathogens in community-acquired pneumonia","volume":"175","author":"Arnold","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2019111315314394200_CIT0008","author":"Centers for Disease Control and Prevention"},{"key":"2019111315314394200_CIT0009","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"2019111315314394200_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"2019111315314394200_CIT0011","author":"US Food and Drug Administration"},{"key":"2019111315314394200_CIT0012","author":"US Food and Drug Administration"},{"key":"2019111315314394200_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39004","article-title":"A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism","volume":"6","author":"Eyal","year":"2016","journal-title":"Sci Rep"},{"key":"2019111315314394200_CIT0014","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/AAC.00358-13","article-title":"Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111315314394200_CIT0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1128\/AAC.05789-11","article-title":"Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections","volume":"56","author":"Sader","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111315314394200_CIT0016","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2019111315314394200_CIT0017","doi-asserted-by":"crossref","first-page":"e02008","DOI":"10.1128\/AAC.02008-16","article-title":"In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111315314394200_CIT0018","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.00627-16","article-title":"In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111315314394200_CIT0019","doi-asserted-by":"crossref","first-page":"e01497","DOI":"10.1128\/AAC.01497-17","article-title":"In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae","volume":"61","author":"Jacobsson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111315314394200_CIT0020","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/jac\/dkv442","article-title":"Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid","volume":"71","author":"Zeitlinger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019111315314394200_CIT0021","unstructured":"Wicha WW , LellC, SeltzerE, PrinceWT, GeloneSP. Pharmacokinetics and safety of an oral, immediate-release (IR) tablet formulation of lefamulin in fed and fasted healthy subjects.Poster presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22\u201325 April 2017."},{"key":"2019111315314394200_CIT0022","volume-title":"Guidance for industry. community-acquired bacterial pneumonia: developing drugs for treatment","author":"US Food and Drug Administration"},{"key":"2019111315314394200_CIT0023","volume-title":"Full prescribing information","author":"AVELOX (moxifloxacin)","year":"2013"},{"key":"2019111315314394200_CIT0024","volume-title":"Recommendations to the FDA for interim endpoints for clinical trials in community-acquired bacterial pneumonia","author":"Foundation for the National Institutes of Health Biomarkers Consortium Project Team","year":"2011"},{"key":"2019111315314394200_CIT0025","volume-title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","author":"Committee for Human Medicinal Products","year":"2013"},{"key":"2019111315314394200_CIT0026","volume-title":"Guidance for industry drug-induced liver injury: premarketing clinical evaluation","author":"US Food and Drug Administration"},{"key":"2019111315314394200_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-017-3000-3","article-title":"Molecular etiological profile of atypical bacterial pathogens, viruses and coinfections among infants and children with community acquired pneumonia admitted to a national hospital in Lima, Peru","volume":"10","author":"Del Valle-Mendoza","year":"2017","journal-title":"BMC Res Notes"},{"key":"2019111315314394200_CIT0028","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019111315314394200_CIT0029","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019111315314394200_CIT0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz090\/30194247\/ciz090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/11\/1856\/30678503\/ciz090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/11\/1856\/30678503\/ciz090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T14:06:29Z","timestamp":1606226789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/11\/1856\/5306243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,2,4]]},"published-print":{"date-parts":[[2019,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz090","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,2,4]]}}}